CDSCO Flags 112 Drug Samples As ‘Not Of Standard Quality’ In September

The Central Drugs Standard Control Organisation (CDSCO) on Thursday announced that the Central and state drugs regulatory authorities tested 112 drug samples.

They found these samples to be ‘Not of Standard Quality (NSQ)’ in their monthly drug alert for September.

The Central Drugs Laboratories identified 52 drug samples as NSQ. Meanwhile, the State Drugs Testing Laboratories flagged 60 drug samples for not meeting quality standards.

As part of routine regulatory surveillance, the CDSCO updates the list of NSQ and spurious drugs every month. They also publish it on the CDSCO portal for public access.

The alert stated, “For September 2025, the Central Drugs Laboratories identified 52 drug samples as Not of Standard Quality (NSQ), and the State Drugs Testing Laboratories identified 60 samples as NSQ”.

Drugs are marked as NSQ when they fail to meet one or more specified quality parameters.

Health officials clarified that this failure is specific to the tested batches and does not raise concerns about other batches of the same drug available in the market.

Additionally, in September, one drug sample from Chhattisgarh was classified as a spurious drug. It was reportedly manufactured by an unauthorised producer using a brand name owned by another company.

Authorities confirmed that the matter is under investigation, and action will be taken according to the Act & Rules.

The CDSCO noted that the process of identifying NSQ and spurious medicines is conducted regularly in collaboration with state regulators to ensure unsafe drugs are removed from the market.

For comparison, in August, 94 drug samples were declared NSQ. Of these, the Central Drugs Laboratories identified 32 samples, while State Drugs Testing Laboratories flagged 62 samples.

Also Read: Early Menopause May Compound Heart And Brain Health Risks, Study Finds